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Abstract: Adaptive designs have been proposed for clinical trials in which the nuisance parameters
or alternative of interest are unknown or likely to be misspecified before the trial. Whereas most
previous works on adaptive designs and mid-course sample size re-estimation have focused on two-
stage or group sequential designs in the normal case, we consider here a new approach that involves
at most three stages and is developed in the general framework of multiparameter exponential
families. Not only does this approach maintain the prescribed type I error probability, but it
also provides a simple but asymptotically efficient sequential test whose finite-sample performance,
measured in terms of the expected sample size and power functions, is shown to be comparable
to the optimal sequential design, determined by dynamic programming, in the simplified normal
mean case with known variance and prespecified alternative, and superior to the existing two-stage
designs and also to adaptive group sequential designs when the alternative or nuisance parameters
are unknown or misspecified.
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1 INTRODUCTION
In standard clinical trial designs, the sample size is determined by the power at a given
alternative (e.g., treatment effect). In practice, especially for new treatments about which
there is little information on the magnitude and sampling variability of the treatment effect,
it is often difficult for investigators to specify a realistic alternative at which sample size de-
termination can be based. Therefore, the problem of sample size re-estimation based on an
observed treatment difference at some time before the prescheduled end of the trial has at-
tracted considerable attention during the past decade; see e.g. Jennison and Turnbull (2000,
Section 14.2), Shih (2001) and Whitehead et al. (2001). Moreover, there are concerns from
the regulatory perspective regarding possible inflation of the type I error probability when
such sample size adjustments are used in pharmaceutical trials. For normally distributed
outcome variables, Proschan and Hunsberger (1995), Fisher (1998), Posch and Bauer (1999),
and Shen and Fisher (1999) have proposed ways to adjust the test statistics after mid-course
sample size modification so that the type I error probability is maintained at the prescribed
level. Jennison and Turnbull (2003) gave a general form of these methods and showed that
they performed considerably worse than group sequential tests. Tsiatis and Mehta (2003) in-
dependently came to the same conclusion, pointing out their inefficiency because the adjusted
test statistics are not sufficient statistics. It is possible to adhere to efficient generalized like-
lihood ratio statistics in a mid-course adaptive design if one uses the non-normal sampling
distribution (due to the mid-course adaptation) of the test statistic, instead of ignoring the
nonnormality and thereby resulting in type I error inflation. A way to do this was proposed
by Li et al. (2002), but it was shown by Turnbull (2006) to be relatively inefficient compared
to group sequential tests. Jennison and Turnbull (2006a) recently introduced adaptive group
sequential tests that choose the jth group size and stopping boundary on the basis of the
cumulative sample size nj−1 and the sample sum Snj−1 over the first j − 1 groups, and that
are optimal in the sense of minimizing a weighted average of the expected sample sizes over
a collection of parameter values subject to prescribed error probabilities at the null and a
given alternative hypothesis. They also showed how the corresponding optimization problem
can be solved numerically by using the backward induction algorithms for “optimal sequen-
tially planned” designs developed by Schmitz (1993). Jennison and Turnbull (2006c) found
that standard (non-adaptive) group sequential tests with the first stage chosen optimally
are nearly as efficient as their optimal adaptive counterparts that are considerably more
complicated, and we use these as a benchmark for our comparisons in Section 3.
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With the goal of achieving similar efficiency in more complicated situations where the
alternative of interest and/or nuisance parameters are not known, we give in Section 2 a
simple adaptive test which updates the sample size after the initial stage by using estimates
of the unknown parameters and adjustments for the uncertainty of these estimates. This
is done first for the one-parameter case in Section 2.1 and extended to the multiparameter
setting in Section 2.3. These tests usually terminate at the first or second stage, but allow
the possibility of a third stage to account for uncertainties in the second-stage sample size
estimate. The tests control the type I error probability and have power close to the uniformly
most powerful fixed sample test. Section 3 gives a comprehensive simulation study, which
is the first of its kind, of the adaptive tests in the aforementioned references and compares
them with the adaptive tests developed in Section 2 and with fixed sample size and standard
group sequential tests having the same minimum and maximum sample sizes. A thorough
evaluation of the performance of these tests is presented, involving the power, mean number
of stages, and the mean, 25th, 50th, and 75th percentiles of the sample size distribution under
a wide range of alternatives, subject to the prescribed constraints on type I error probability
and first-stage and maximum sample sizes. Section 3.1 also compares the proposed adaptive
test with the benchmark optimal adaptive test of Jennison and Turnbull (2006a; 2006c), and
the variance unknown case is considered in Section 3.2. An example from the National Heart,
Lung and Blood Institute Coronary Intervention Study is given in Section 3.3. Section 4
gives some concluding remarks.
2 EFFICIENT ADAPTIVE TESTS WITH THREE
OR FEWER STAGES
In this section we consider one-sided tests of the null hypothesis H0 : θ ≤ θ0 on the natural
parameter θ in a one-parameter exponential family fθ(x) = e
θx−ψ(θ) of densities with respect
to some measure on the real line. Let X1, X2, . . . denote the successive observations, and let
Sn = X1 + . . . + Xn. A sufficient statistic based on (X1, . . . , Xn) is X¯n = Sn/n, and the
maximum likelihood estimate of θ is θ̂n = (ψ
′)−1(X¯n). The special case of normal Xi with
mean θ and known variance 1 is widely used in the literature on sample size re-estimation as
a prototype which can be used to approximate more complicated situations via the central
limit theorem, as in the references in Section 1.
In practice, there is an upper bound M on the allowable sample size for a clinical
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trial because of funding and duration constraints and because there are other trials that
compete for patients, investigators and resources. The re-estimated sample size in two-stage
designs has to be restricted within this bound; see, e.g., Li et al. (2002, p. 283). Lai and
Shih (2004, p. 511) have pointed out that M implies constraints on the alternatives that
can be considered in power calculations to determine the sample size. Specifically, by the
Neyman-Pearson lemma, the fixed sample size (FSS) test that rejects H0 if SM ≥ cα,M has
maximal power at any alternative θ > θ0, and in particular at the alternative θ1 at which the
FSS test has prescribed power 1− α˜. Here cα,n denotes the critical value of the level-α FSS
test based on a sample of size n, i.e., prθ0{Sn ≥ cα,n} = α. Typical sample size re-estimation
procedures in the literature (see, e.g., the references in Section 1) first use the initial sample
of size m, which is some fraction of M , to provide an estimate θ̂m of θ and then evaluate
the sample size of the FSS test that has conditional power 1 − α˜ given the alternative θ̂m,
assuming that θ̂m > θ0. This results in a two-stage procedure, which does not incorporate the
sampling variability of the estimate θ̂m. A simple way to make “uncertainty adjustments”
in the above procedure that attempts to “self-tune” itself to the actual θ value is to allow
the possibility of not stopping at the second stage when H0 is not rejected, by including a
third (and final) stage with total sample size M .
2.1 An Efficient Test of H0 with At Most Three Stages
To test H0 : θ ≤ θ0 at significance level α, suppose no fewer than m but no more than M
observations are to be taken. Let θ1 be the alternative “implied” by M , in the sense that
M can be determined as the sample size of the level-α Neyman-Pearson test with power
1 − α˜ at θ1. Alternatively, θ1 can be specified separately from M as a clinically relevant
or realistic anticipated effect size based on prior experimental, observational, or theoretical
evidence, if such information is available. A fundamental result in sequential testing theory
is that Wald’s sequential probability ratio test (SPRT) of the simple hypotheses θ = θ′ vs.
θ = θ′′ has the smallest expected sample size at θ = θ′ and θ′′ among all tests with the same
or smaller type I and II error probabilities; see Reference (1972). Moreover, letting α and α˜
denote the the type I and II error probabilities and T (θ′, θ′′) be the sample size of the SPRT,
Chernoff (1972, p. 66) has derived the approximations
Eθ′′(T (θ
′, θ′′)) ≈ | logα|/I(θ′′, θ′), Eθ′(T (θ′, θ′′)) ≈ | log α˜|/I(θ′, θ′′), (2.1)
where
I(θ, λ) = Eθ[log{fθ(Xi)/fλ(Xi)}] = (θ − λ)ψ′(θ)− {ψ(θ)− ψ(λ)}
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is the Kullback-Leibler information number. To test the one-sided hypothesis H0 : θ ≤ θ0,
suppose that we use the maximum likelihood estimator θ̂m from the first stage of the study in
place of the alternative θ′′ in (2.1) with θ′ = θ0, in the event θ̂m > θ0. Then the first relation in
(2.1) suggests that an efficient second-stage sample size would be around | logα|/I(θ̂m, θ0).
On the other hand, if θ̂m ≤ θ0, then we can consider the possibility of stopping due to
futility by choosing θ′ = θ̂m and θ
′′ = θ1 in the SPRT, so the second relation in (2.1)
suggests | log α˜|/I(θ̂m, θ1) as an efficient second-stage sample size. Adjusting for the sampling
variability in θ̂m by inflating by the factor 1+ρm, we therefore define the second stage sample
size
n2 = m ∨ {M ∧ ⌈(1 + ρm)n(θ̂m)⌉}, (2.2)
where ρm > 0, ∨ and ∧ denote maximum and minimum, respectively, ⌈x⌉ denotes the
smallest integer ≥ x (and ⌊x⌋ denotes the largest integer ≤ x), and
n(θ) =
| logα|
I(θ, θ0)
∧ | log α˜|
I(θ, θ1)
, (2.3)
which is an approximation to Hoeffding’s (1960) lower bound for the expected sample size
Eθ(T ) of a test that has type I error probability α at θ0 and type II error probability α˜ at
θ1. Note that (2.2) includes the cases n2 = m and n2 =M associated with using just one or
two stages. Moreover, the stopping rule defined below by (2.4)-(2.6) allows the possibility of
stopping after the first or second stage. Therefore, the actual number of stages used by the
“three-stage” test is in fact a random variable taking the values 1, 2, 3.
The three-stage test uses rejection and futility boundaries similar to those of the efficient
group sequential tests introduced by Lai and Shih (2004). Letting ni denote the total sample
size at the ith stage, the test stops at stage i ≤ 2 and rejects H0 if
ni < M, θ̂ni > θ0, and niI(θ̂ni , θ0) ≥ b, (2.4)
where n1 = m and n2 is given by (2.2). The test stops at stage i ≤ 2 and accepts H0 if
ni < M, θ̂ni < θ1, and niI(θ̂ni , θ1) ≥ b˜. (2.5)
It rejects H0 at stage i = 2 or 3 if
ni = M, θ̂M > θ0, and MI(θ̂M , θ0) ≥ c, (2.6)
accepting H0 otherwise. Letting 0 < ε, ε˜ < 1, define the thresholds b, b˜, and c by the
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equations
prθ1{(2.5) occurs for i = 1 or 2} = ε˜α˜, (2.7)
prθ0{(2.5)does not occur for i ≤ 2, and (2.4) occurs for i = 1 or 2} = εα, (2.8)
prθ0{(2.4) and (2.5) do not occur for i ≤ 2, and (2.6) occurs} = (1− ε)α. (2.9)
Note that (2.8) and (2.9) imply that the type I error probability is exactly α, and we have
found in our simulations (see Section 3) that the power at θ1 is generally close to, but slightly
less than, 1− α˜. The values ε, ε˜ are the fractions of type I and II error probabilities “spent”
at the first two stages, and in theory any values 0 < ε, ε˜ < 1 may be used. In practice, we
recommend using 0.2 ≤ ε, ε˜ ≤ 0.8 and we have found that the power and expected sample
size of the above adaptive test vary very little with changes in ε, ε˜. In particular, the three
examples in Section 3 use ε = ε˜ = 1/3, (ε, ε˜) = (1/2, 3/4), and ε = ε˜ = 1/2. The factor ρm
in (2.2) is a small inflation of n(θ̂m) to adjust for the uncertainty in θ̂m. Lorden (1983) gives
an asymptotic upper bound for ρm as a function of θ0, θ1, α, and α˜. We advocate simply
fixing ρm to a small maximum inflation that the practitioner is comfortable with, and have
found that ρm = .05 or .1 works well in practice, which we use in the examples in Section 3.
As with M , the choice of m is often determined by practical considerations like funding and
duration. To aid such considerations or in the absence of them, if the practitioner has bounds
θ < θ0 and θ > θ1 in mind (e.g., θ might be the largest realistic treatment effect likely to
be seen), then m could be chosen to be n(θ)∧ n(θ), an approximation to Hoeffding’s (1960)
lower bound for the smallest expected sample size of a test with error probabilities α, α˜ at
θ0, θ1 when θ = θ or θ.
The probabilities in (2.7)-(2.9) can be computed by Monte Carlo or recursive numerical
integration, using normal approximations to signed-root likelihood ratio statistics. Further
details are given in Section 2.2. The original idea to use (2.2) as the second-stage sample
size and to allow the possibility of a third stage to account for uncertainty in the estimate
θ̂m (and hence n2) is due to Lorden (1983), although his test uses very conservative upper
bounds on the error probabilities. Here we have modified Lorden’s test to control the type
I error α exactly, and provided algorithms to implement the modified test. It can be shown
that our three-stage test is asymptotically optimal: If N is the sample size of our three-stage
test above, then
Eθ(N) ∼ m ∨
{
M ∧ | logα|
I(θ, θ0) ∨ I(θ, θ1)
}
(2.10)
as α + α˜ → 0, logα ∼ log α˜, ρm → 0 and ρm
√
m/ logm → ∞; and if T is the sample size
of any test of H0 : θ ≤ θ0 whose error probabilities at θ0 and θ1 do not exceed α and α˜,
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respectively, then
Eθ(T ) ≥ (1 + o(1))Eθ(N) (2.11)
simultaneously for all θ. The proof uses Hoeffding’s (1960) lower bound for Eθ(T ) as in
(1983) and can be found in (2007).
Since logα ∼ log(εα) as α → 0 for any fixed 0 < ε < 1, the asymptotic formula for
Eθ(N) in (2.10) is unchanged if one replaces the type I error probability α by a fraction of
it, and this is why Lorden (1983) can use crude bounds of the type above for the type I error
probability. For values of the type I error probability α (e.g., .05 or .01) commonly used in
practice, replacing α by α/10, say, can substantially increase Eθ(N). Note that our adaptive
test keeps the error probability at θ0 to be α (instead of less than α) by using Monte Carlo
or recursive numerical integration to evaluate it, discussed in the next section.
2.2 The Normal Case and Recursive Numerical Integration
The thresholds b, b˜, and c can be computed by solving in succession (2.7), (2.8), and (2.9).
Univariate grid search or Brent’s method (1992) can be used to solve each equation. Suppose
the Xi are N(θ, 1). Without loss of generality, we shall assume that θ0 = 0. Since I(θ, λ) =
(θ − λ)2/2, we can rewrite (2.7) as
prθ1{Sm −mθ1 ≤ −(2b˜m)1/2}
+ prθ1{Sm −mθ1 > −(2b˜m)1/2, Sn2 − n2θ1 ≤ −(2b˜n2)1/2} = ε˜α˜
(2.12)
and (2.8) and (2.9) as
pr0{Sm/
√
2m ≥ b1/2}+ pr0{b˜1/2 < Sm/
√
2m < b1/2, Sn2/
√
2n2 ≥ b1/2} = εα, (2.13)
pr0{b˜1/2 < Sm/
√
2m < b1/2, b˜1/2 < Sn2/
√
2n2 < b
1/2, SM/
√
M ≥ c1/2} = (1− ε)α. (2.14)
The probabilities involving n2 can be computed by conditioning on the value of Sm/m, which
completely determines the value of n2, denoted by k(x). For example, the probabilities under
θ = 0 can be computed via
pr0{Sn2 ≥ (2bn2)1/2|Sm = mx} = Φ
(
mx− [2bk(x)]1/2
[k(x)−m]1/2
)
, (2.15)
pr0{Sn2 ∈ dy, SM ∈ dz|Sm = mx} = ϕk(x)−m(y −mx)ϕM−k(x)(z − y)dydz, (2.16)
where Φ is the standard normal c.d.f. and ϕv is the N(0, v) density function, i.e., ϕv(w) =
(2πv)−1/2 exp(−w2/2v). The probabilities under θ1 can be computed similarly. Hence stan-
dard recursive numerical integration algorithms can be used to compute the probabilities in
(2.7)-(2.9).
6
As an example, we compute the thresholds b, b˜, and c for the following adaptive test
whose performance is studied in Section 3.1. Here M = 120, α = .025, and we want the
power to be close to 1 − α˜ = .9 at θ = θ1 = .3. Setting ε = ε˜ = 1/3 and ρm = .1, we first
find b˜ by solving (2.12), which can be written as
Φ(−[2b˜]1/2) +
∫
∞
[2b˜/m]1/2
Φ
(
−m(x− θ1)− [2b˜k(x)]1/2
[k(x)−m]1/2
)
ϕm(mx)mdx = ε˜α˜ =
0.1
3
by the analog of (2.15) for θ = θ1, where ϕv is as in (2.16). The integral is computed by
numerical integration and a few iterations of the bisection method gives b˜ = 1.99. This value
is next used to find b similarly by solving (2.13), which can be written as
Φ(−[2b]1/2) +
∫ [2b/m]1/2
[2b˜/m]1/2
Φ
(
mx− [2bk(x)]1/2
[k(x)−m]1/2
)
ϕm(mx)mdx = εα =
0.025
3
by (2.15). The bisection method gives b = 3.26, which we in turn use to find c by solving
(2.14), which is∫ [2b/m]1/2
[2b˜/m]1/2
∫ [2bk(x)]1/2
[2b˜k(x)]1/2
Φ
(
[cM ]1/2 − y
[M − k(x)]1/2
)
ϕk(x)−m(y −mx)ϕm(mx)mdydx = (1− ε)α = 0.05
3
by (2.16), giving c = 2.05.
2.3 Multiparameter Extension
Suppose X1, X2, . . . are independent d-dimensional random vectors from a multiparameter
exponential family fθ(x) = exp{θTx−ψ(θ)} of densities. The three-stage test in Section 2.1
can be readily extended to test H0 : u(θ) ≤ u0, where u is any smooth real-valued function.
As in Section 2.1, n1 = m and n3 = M . The stopping rule of the three-stage test of
H0 : u(θ) ≤ u0 is the same as (2.4)-(2.6) but with nI(θ̂n, θj) replaced by
inf
θ:u(θ)=uj
nI(θ̂n, θ), (2.17)
j = 0, 1, where u1 > u0 is the alternative implied by the maximum sample size M and the
desired type II error probability α˜; see (2004, Section 3.4). In particular, the test stops and
rejects H0 at stage i ≤ 2 if
ni < M, u(θ̂ni) > u0, and inf
θ:u(θ)=u0
niI(θ̂ni , θ) ≥ b, (2.18)
which is analogous to (2.4). Early stopping for futility (accepting H0) can also occur at stage
i ≤ 2 if
ni < M, u(θ̂ni) < u1, and inf
θ:u(θ)=u1
niI(θ̂ni , θ) ≥ b˜, (2.19)
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which is analogous to (2.5). The test rejects H0 at stage i = 2 or 3 if
ni =M, u(θ̂M) > u0, and inf
θ:u(θ)=u0
MI(θ̂M , θ) ≥ c, (2.20)
accepting H0 otherwise. The thresholds b, b˜, and c are chosen to ensure certain type I and
type II error probability constraints that are similar to (2.7)-(2.9) and are computed by using
the normal approximation to the signed-root likelihood ratio statistic
ℓn(δ) = n{sign(u(θ̂n)− δ)}{2 inf
θ:u(θ)=δ
I(θ̂n, θ)}1/2
under the hypothesis u(θ) = δ; see (2004, p. 513). Note that this normal approximation can
be used for the choice of u1 implied by the maximum sample size M and the type II error
probability α˜. The sample size n2 of the three-stage test is given by (2.2) with
n(θ) = min{| logα|/ inf
λ:u(λ)=u0
I(θ, λ), | log α˜|/ inf
λ:u(λ)=u1
I(θ, λ)}, (2.21)
which is a generalization of (2.3). Examples of the multiparameter case are given in Sec-
tion 3.2 for normally distributed data with unknown variance, and in Section 3.3 for two
binomial populations.
3 COMPARISON WITH OTHER TESTS
3.1 Normal Mean with Known Variance
We consider the special case of normal Xi with unknown mean θ and known variance 1, and
compare a variety of adaptive tests of H0 : θ ≤ 0 in the literature with the tests proposed
in Section 2.1. In this normal setting, θ̂n = Xn and I(θ, λ) = (θ − λ)2/2. It is widely
recognized that the performance of adaptive tests is difficult to evaluate and compare because
it depends heavily on the choice of first-stage and maximum sample sizes, the number of
groups (stages) allowed, and the parameter values at which the tests are evaluated. For this
reason, the tests evaluated here use the same first-stage and maximum sample sizes, except
for a few illustrative examples discussed below. In addition, we report a variety of operating
characteristics for each test – power, mean number of stages, and the 25th, 50th, and 75th
percentiles in addition to the mean of the sample size distribution – over a wide range of
θ values. A comprehensive evaluation of adaptive and group sequential tests like this has
not appeared previously in the literature. We also include the uniformly most powerful FSS
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test with the same maximum sample size and type I error probability α, which provides
the appropriate benchmark for the power of any test of H0. Another relevant comparison
– especially given their widespread use in clinical trials – made here is with standard (non-
adaptive) group sequential tests having a similar number of stages as the adaptive test.
To test H0 : θ ≤ 0, Proschan and Hunsberger (1995) proposed a two-stage test, based on
the conditional power criterion, which uses the usual z-statistic but with a data-dependent
critical value to maintain the type I error at a prescribed level α. The test allows early stop-
ping to accept (or reject) the null hypothesis if the test statistic is below a user-specified upper
normal quantile zp∗ (or above some level k) at the end of the first stage. Choosing a data-
dependent critical value is tantamount to multiplying the z-statistic by a data-dependent
factor and using a fixed critical value. Li et al. (2002) proposed to use the z-statistic with
a fixed critical value c, while still determining the second-stage sample size by conditional
power and maintaining the type I error at α. Their test stops after the first stage if the
test statistic falls below h or above k. For each h and conditional power level, their test
has a maximum allowable k, which they denote by k∗1(h). Fisher (1998) proposed a “vari-
ance spending” method for weighting the observations so that the type I error of his test
does not exceed α, despite its data-dependent second-stage sample size that is given by the
conditional power criterion. To avoid a very large second-stage sample size if the first-stage
estimate of θ lies near the null hypothesis, Shen and Fisher (1999) proposed early stopping
due to futility whenever the upper 100(1 − α0)% confidence bound for θ falls below some
specified alternative θ1 > 0
Table 1 compares these tests, a FSS test, and two standard group sequential tests with
the adaptive test described in Section 2.1. The values of the user-specified parameters of
the tests are summarized in the list below. The user-specified parameters are chosen so
that they have the same first-stage sample size m = 40 (except for the FSS test), maximum
sample size M = 120 (except for SF′; see the last paragraph of this section), type I error not
exceeding α = .025, and nominal power (or conditional power level in the case of conditional
power tests) equal to .9.
• ADAPT: The adaptive test described in Section 2.1 that uses b = 3.26, b˜ = 1.99, and
c = 2.05 corresponding to ε = ε˜ = 1/3 in (2.7)-(2.9), and ρm = .1 (see Section 2.2 for
details).
• FSS120: The FSS test having sample size 120.
• OBFPF , OBFSC: O’Brien and Fleming’s (1979) one-sided group sequential tests having
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three groups of size 40. OBFPF uses power family futility stopping (∆ = 1 in (2000,
Section 4.2)) and OBFSC uses stochastic curtailment futility stopping (γ = .9 in (2000,
Section 10.2)). Both OBFPF and OBFSC use reference alternative θ1 = .3; see below.
• PH: Proschan and Hunsberger’s (1995) test that uses p∗ = .0436 and k = 2.05.
• L: Li et al.’s (2002) test that uses h = 1.63 and k = k∗1(h) = 2.83.
• SF, SF′: Two versions of Shen and Fisher’s (1999) test; SF uses α0 = .425 and SF′
uses α0 = .154.
The tests are evaluated at the θ values where FSS120 has power .01, .025, .6, .8, .9, .95,
and at θ = .15, the midpoint of θ = 0 and θ = θ1 = .3, the alternative implied by M = 120
since FSS120 has power 1 − α˜ = .9 there. This is also the alternative used by the OBF
tests for futility stopping. Each entry in Table 1 is computed by Monte Carlo simulation
with 100,000 replications. To compare tests T , T ′ with type I error probability α but with
different type II error probabilities α˜T (θ), α˜T ′(θ) and expected sample sizes EθT , EθT
′ at
θ > 0, Jennison and Turnbull (2006a) defined the efficiency ratio of T to T ′:
Rθ(T, T
′) =
(zα + zα˜T (θ))
2/EθT
(zα + zα˜T ′ (θ))
2/EθT ′
× 100, (3.1)
noting that (zα + zα˜T (θ))
2/θ2 is the sample size of the FSS test with the same type I error
probability and power as T . Table 1 contains Rθ(T,N) for all tests T and θ > 0, where N
is the sample size of ADAPT.
INSERT TABLE 1 ABOUT HERE
ADAPT has power comparable to FSS120 at all values of θ while achieving substantial
savings in sample size, as shown by the percentiles and mean of the sample size. The three-
stage OBF tests have power comparable to ADAPT and FSS120, but ADAPT has sample
size savings over the OBF tests, especially for larger θ > 0, reflected by the efficiency ratio.
The mean number of stages (denoted by #) reveals that although ADAPT allows for the
possibility of three stages, most frequently it uses only one or two stages.
The conditional power tests PH, L, SF, and SF′ are underpowered at values of θ > 0 in
Table 1. In particular, PH, L, and SF all have power less than .6 at θ1 = .3, where ADAPT,
FSS120, and the OBF tests have power around .9. The lack of power of PH, L, and SF shown
by Table 1 is caused by stopping too early for futility. For example, the PH test stops for
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futility after the first stage if Sm/
√
m falls below zp∗ = 1.71. But prθ1{Sm/
√
m < 1.71} = .44,
well exceeding the nominal type II error of .1. On the other hand, such stringent futility
stopping is necessary to control the sample size of conditional power tests. For example, the
.025-level PH test that stops for futility only when θ̂m ≤ 0 (i.e., with p∗ = .5) has expected
sample size greater than 107 at all values of θ in Table 1, yet power less than .9 at θ1. SF
and SF′ provide another example of this behavior. Since these tests stop for futility at the
first stage when Sm/m ≤ θ1 − zα0/
√
m, the choice of α0 determines the maximum sample
size. For maximum sample size M = 120, SF uses α0 = .425, a high rate of first-stage
futility stopping which results in small expected sample sizes, low power, and a reduced type
I error of .012, which is α = .025 in the absence of futility stopping. In contrast, SF′ uses
less stringent futility stopping with α0 = .154 that corresponds to maximum sample size
5M = 600, which results in a type I error closer to .025 and better power, though it is still
underpowered and its expected sample size exceeds 120 at .2 ≤ θ ≤ .26. The smallest α0
that does not perturb the type I error of .025 of Shen and Fisher’s test is α0 = .039, but the
resultant test has expected sample size 1856 at θ = 0 and maximum sample size 52341.
INSERT TABLE 2 ABOUT HERE
The efficiency ratios relative to ADAPT in Table 1 are all less than 100 with the exception
of PH, L, and SF at θ = .15, but it is not clear that the efficiency ratio has much meaning
in this case where the power of these tests is so low. For the other cases, it is natural to ask
if much more improvement is possible. A benchmark for answering this question is provided
by the optimal adaptive tests of Jennison and Turnbull (2006a; 2006c) that minimize the
expected sample size averaged over a collection of θ values, subject to a given type I error
probability and power level at a prespecified alternative θ′. Table 2 contains the expected
sample size of T ∗k , the k-stage test minimizing
[E0(T ) + Eθ′(T ) + E2θ′(T )]/3 (3.2)
among all k-stage tests with maximum sample sizeM = 120, type I error probability α = .025
and power .8 at θ′, the alternative where FSS100 has power .8, from (2006c, Table III). To
this benchmark we compare ADAPT with the same first group size m = 29 as T ∗3 , M = 120,
θ1 fixed at θ
′, and b = 2.94, b˜ = .7, and c = 2.05 corresponding to ε = 1/2, ε˜ = 3/4.
Also included in Table 2 is the optimal k-stage “ρ-family” group sequential test (denoted by
OGS(k)) withM = 120, groups 2, . . . , k of size (M−m)/(k−1), and with m and ρ chosen to
minimize (3.2). Jennison and Turnbull (2006c) concluded that OGS(k) is a computationally
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easier alternative to T ∗k , and Table 2 shows that their expected sample sizes are close at
θ = 0, θ′, 2θ. Note that ADAPT has expected sample size close to OGS(3) and T ∗3 even
though the probability that ADAPT uses only 1 or 2 stages is 96.4%, 83.1%, and 98.4% for
θ = 0, θ′, and 2θ′, respectively, showing that ADAPT very often behaves like a 2-stage test.
ADAPT has substantially smaller expected sample size than T ∗2 and OGS(2), however. On
the other hand, T ∗4 is more efficient than ADAPT but this is due in part to its smaller first
group of m = 24, afforded by its additional stage. Here we have matched the first group
m = 29 of ADAPT to the that of T ∗3 for the purpose of comparison, but in practice there is
flexibility in its choice of m. The T ∗k and OGS(k) tests, on the other hand, are rigid in their
choice of m that is determined by dynamic programming from the prespecified alternative
θ′, about which there may be some uncertainty before the trial.
Lokhnygina (2004), who considers somewhat different objective functions than (3.2), has
computed and plotted the data-dependent total sample size of the optimal 2-stage design as
a function of the first stage sample mean Xm. Her results show the total sample size to be
a unimodal function of Xm, peaking between 0 and θ
′. For comparison, Figure 1 plots the
function n(θ) (2.3) in the sample size updating rule (2.2) of ADAPT for the setting of Table 2.
A similar shape is exhibited by Figure 2.2 of (2004) on the total sample size function (which
is m plus the second-stage sample size) of the optimal two-stage test. This is not surprising
because to be optimal, the expected sample size cannot differ much from Hoeffding’s (1960)
lower bound, of which n(θ) is a close approximation. Figure 1 differs dramatically from
the total sample size function of any untruncated two-stage conditional power rule which
increases to infinity as θ̂m approaches 0. Jennison and Turnbull (2006b, p. 672) have also
pointed this out and suggested that this is a source of inefficiency of two-stage conditional
power tests.
INSERT FIGURE 1 ABOUT HERE
3.2 Case of Unknown Variance
The optimal adaptive test T ∗k and the optimal group sequential tests OGS(k) in Table 2
require the variance of the observations to be known. As pointed out above, in practice
there is often little information about the sampling variability before the trial. Dynamic
programming is difficult to carry out for the optimal adaptive test when the X1, X2, . . . are
i.i.d. N(µ, σ2) and both µ and σ are unknown, and no analog of T ∗k has been developed in this
setting. However, the optimal group sequential tests OGS(k) in Table 2 can be modified for
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the present setting by applying their error spending functions to the sequential t-statistics,
as described in (2000, Section 11.5), which are denoted by OGS∗(k). In this section we
compare ADAPT with OGS∗(k) and other tests for a normal mean when the variance is
unknown. In the notation of Section 2.3, θ = (µ, σ)T , u(θ) = µ, u0 = 0, and the generalized
likelihood ratio statistic (2.17) is
(n/2) log
[
1 +
(
Xn − uj
σ̂n
)2]
,
where σ̂n is the MLE of σ. Denne and Jennison (2000) proposed an adaptive group-sequential
extension of Stein’s (1945) 2-stage t-test in which the total sample size and stopping bound-
aries are updated at each stage as a function of the current estimate of σ2. Lai and Shih (2004)
introduced tests of composite hypotheses for a multiparameter exponential family which use
the same stopping rule (2.18)-(2.20) as ADAPT but with prespecified group sizes. The ex-
pected number of stages, power and expected sample size of these tests are given in Table 3
at various (µ, σ) values. All tests use m = 34 (with the exception of OGS∗(4)) and M = 120
(with the exception of DJ which has unbounded maximum sample size), the first stage and
maximum sample sizes of OGS(3) in Section 3.1, and nominal power levels α = .025 and
1 − α˜ = .8 at (µ, σ) = (0, 1) and (θ′, 1), respectively, where θ′ is as in Section 3.1. Other
values of the user-specified parameters of the tests are listed below.
• ADAPT: The adaptive test described in Section 2.3 with u1 fixed at θ′, b = 2.49,
b˜ = .59 and c = 2.7 corresponding to ε = 1/2, ε˜ = 3/4.
• OGS∗(k): Jennison and Turnbull’s (2000, Section 11.5) group sequential t-test with
k groups and the same m and error spending function as that of OGS(k) in Table 2:
OGS∗(3) uses ρ = .99 and group sizes 34, 43, 43; OGS∗(4) uses ρ = 1.13 and group
sizes 29, 30, 30, 31.
• DJ: The adaptive 3-stage t-test of Denne and Jennison (2000) with ρ = .99, to match
OGS∗(3).
• LS: Lai and Shih’s (2004, Section 3.4) group sequential test with group sizes 34, 43,
43, so that m = 34 and M = 120.
INSERT TABLE 3 ABOUT HERE
When σ = 1, ADAPT, OGS∗, and DJ have similar power and expected sample size
properties, with ADAPT having the smallest expected number of stages and smaller expected
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sample size than OGS∗(3). LS has the highest power of the five tests, but highest expected
sample size too. When σ < 1 and µ = 0, ADAPT has substantially smaller expected sample
size than OGS∗(3) and even OGS∗(4). DJ has similar operating characteristics to ADAPT
and LS when σ < 1. However, when σ > 1, the expected sample size of DJ becomes much
larger than those of other tests because its total sample size is chosen to be proportional
to the estimate of σ2 at the end of the previous stage. In all cases evaluated, ADAPT has
the smallest expected number of stages, less than 2 in each case, showing that it most often
behaves like a FSS or 2-stage test, as in the variance known setting of Table 1.
3.3 Coronary Intervention Study
The National Heart, Lung and Blood Institute (NHLBI) Type II Coronary Intervention
Study (1982) was designed to investigate the cholesterol-lowering affects of cholesytyramine
on patients with Type II hyperlipoproteinemia and coronary artery disease. Patients were
randomized into cholesytyramine and placebo groups, and coronary angiography was per-
formed before and after five years of treatment. It was found that the disease had progressed
in 20 of 57 in the placebo group and 15 of 59 in the cholesytyramine group. Proschan and
Hunsberger (1995) and Li et al. (2002) have considered how this study could have been
extended by using their two-stage tests for the difference in two normal means with common
unknown variance. To apply these tests to the NHLBI study, they assumed the first-stage
sample size to be 58 = (57+ 59)/2 for the normal problem and used the arcsine transforma-
tion so that the difference between the transformed binomial frequencies, p1 for the placebo
group and p2 for the treatment group, is approximately normally distributed; details are
given in the next paragraph. As an alternative we apply the three-stage test in Section 2.3
to two binomial populations. In the notation of Section 2.3, to test H0 : p2 ≤ p1 we have
θ = (p1, p2)
T , u(θ) = p2−p1, u0 = 0, and the test statistic infθ:u(θ)=δ nI(θ̂n, θ) in (2.18)-(2.20)
takes the form
n
{
p̂1,n log
(
p̂1,n
pδ,n
)
+ q̂1,n log
(
q̂1,n
1− pδ,n
)
+ p̂2,n log
(
p̂2,n
pδ,n + δ
)
+ q̂2,n log
(
q̂2,n
1− pδ,n − δ
)}
,
where p̂i,n is the maximum likelihood estimator of pi based on n observations, q̂i,n = 1− p̂i,n,
and pδ,n is the maximum likelihood estimator of p1 under the assumption p2 − p1 = δ. The
treatment and placebo groups are assumed to have the same per-group sample size during
interim analyses, following Proschan and Hunsberger (1995) and Li et al. (2002).
Letting Sn denote the sum of independent normal random variables with mean µ and
variance 1, following a pilot study of size m resulting in Sm = sm, Proschan and Huns-
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berger’s (1995) test chooses n2 and critical value c to satisfy the conditional power criterion
pr{Sn2/n1/22 > c|Sm = sm, µ = sm/m1/2} ≥ 1− α˜ (3.3)
and type I error constraint
pr0{Sn2/n1/22 > c|Sm = sm} = α. (3.4)
In order to solve for n2 and c, a parametric form for the probability in (3.4) is assumed,
which contains a user-specified futility boundary h and critical value k for the internal pilot.
Li et al. (2002) introduce a modification of Proschan and Hunsberger’s (1995) test in which
the critical value c is specified before the internal pilot study but h, k, and n2 are chosen to
satisfy (3.3) and (3.4) after the internal pilot study. This modification allows approximations
to the probabilities in (3.3) and (3.4) to be used in lieu of a specific parametric form. For the
coronary intervention study, Proschan and Hunsberger (1995) and Li et al. (2002) propose
using these tests with the variance-stabilizing transformation Sn = (2n)
1/2{arcsin(p̂1/21,n) −
arcsin(p̂
1/2
2,n )}.
INSERT TABLE 4 ABOUT HERE
Table 4 gives the power, per-group expected sample size, and efficiency ratio (3.1), using
the normal approximation, relative to ADAPT (for alternatives p2 > p1) of the following
tests for various values of p1, p2 near 15/59 = .254 and 20/57 = .351, the values observed in
the NHLBI study (1982).
• L: Li et al.’s (2002) test with h = 1.036, k = 1.82, c = 1.7, α = .05, conditional power
level .8, and first-stage size m = 58.
• PH: Proschan and Hunsberger’s (1995) test with h = 1.036, k = 1.82, α = .05,
conditional power level .8, and first-stage size m = 58.
• ADAPT: The adaptive test described in a previous paragraph with m = 58, M = 302
(the maximum sample size of L), and thresholds b = 2.36, b˜ = 1.1, and c = 1.55
corresponding to α = .05, α˜ = .2, and ε = ε˜ = 1/2.
All three tests use the same first-stage size m = 58. ADAPT matches the maximum sample
size M = 302 of L, and the parameters of PH determine its maximum sample size to be
slightly larger at 354. The actual power of L and PH is around 50% for the values of p1 and
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p2 in Table 4 with p2 − p1 = .1, and is less than 50% when p1 = .254 and p2 = .351 where
they were designed to have conditional power 80%. This is caused in part by premature
stopping for futility at the end of the first stage. Indeed, L and PH use the same futility
boundary and their probability of stopping at the end of the first stage when p1 = .254 and
p2 = .351 is .47, well exceeding the nominal Type II error probability .2. One might ask if a
conditional power test can avoid this phenomenon by using a larger first-stage sample size
so that the estimate p̂2 − p̂1 is near 0 less often after the first stage when the true difference
p2 − p1 is substantially greater than 0. If the first-stage sample size of L is raised to 162
(raising the maximum sample size to 1331), the resultant test has power 79% when p1 = .254
and p2 = .351, approximately equal the power of ADAPT. However, the expected sample
size of this version of L is 264 at this alternative, compared to the expected sample size
213.1 of ADAPT. Similar oversampling also occurs for the values of p1 and p2 in Table 4
with p2 − p1 > .1, where the power of L and PH is closer to the nominal conditional power
level of 80%, but the efficiency ratio drops to around 75%.
4 DISCUSSION
Most previous works in the literature on adaptive design of clinical trials and mid-course
sample size adjustments have focused on two-stage designs whose second-stage sample size
is determined by the results from the first stage using conditional power. Although this
approach is intuitively appealing, it does not adjust for the uncertainty in the first-stage
parameter estimates that are used to determine the second-stage sample size. This can result
in substantial power loss, as shown in Section 3.1. Although Jennison and Turnbull (2003)
and Tsiatis and Mehta (2003) have pointed out the inefficiency of this approach and advocate
instead using group sequential designs, their critique focuses on the use of non-sufficient
“weighted” test statistics and variability in the interim estimate. Through our extensive
simulation studies we have shown that another problem with conditional power methods in
practice is potential lack of power, which results from the difficulty in bridging conditional
power with actual power and in choosing a futility stopping rule.
In their recent survey of adaptive designs, Burman and Sonesson (2006) pointed out
that previous criticisms of the statistical principles and properties of these designs may be
unconvincing in some situations when flexibility and not having to specify parameters that
are unknown at the beginning of a trial (like the relevant treatment effect or variance) are
more imperative than efficiency or being powerful, whereas most efficient group sequential
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designs require the prespecification of the relevant alternative and variance, as in the case of
the optimal adaptive tests of Jennison and Turnbull (2006a; 2006c). Moreover, conditional
power tests are easy to implement while optimal adaptive tests require substantial dynamic
programming computations. The adaptive tests of Section 2 combine the attractive features
of both the conditional power and group sequential tests. Rather than achieving exact opti-
mality at a specified collection of alternatives through dynamic programming, they achieve
asymptotic optimality over the entire range of alternatives, resulting in near-optimality in
practice; see Section 3.1. These tests are based on efficient generalized likelihood ratio statis-
tics which have an intuitively “adaptive” appeal via estimation of unknown parameters by
maximum likelihood, ease of implementation, and freedom from having to specify the rel-
evant alternative (through the implied alternative) that conditional power tests enjoy. As
shown in Section 2.3, these generalized likelihood ratio statistics and the associated adaptive
tests can be readily extended to multiparameter settings with nuisance parameters and they
enjoy near-optimality in these more complicated and realistic settings as well; see Sections 3.2
and 3.3.
The possibility of adding a third stage to improve two-stage designs dated back to Lor-
den (1983), who used upper bounds for the type I error probability that are overly conser-
vative for applications to clinical trials, which need to maintain the type I error probability
of the test at a prescribed level because of regulatory and publication requirements; see the
references in Section 1. We have modified Lorden’s three-stage test by combining its basic
features to preserve its asymptotic optimality with those of Lai and Shih (2004) for efficient
group sequential designs. The adaptive test in Section 2 makes use of the maximum sample
size M to come up with an implied alternative which is used to choose the rejection and
futility boundaries appropriately so that the test does not lose much power in comparison
with the (most powerful) FSS test of the null hypothesis versus the implied alternative. This
idea has led to the superior power properties of ADAPT in Table 1, comparable to those of
the FSS test. Moreover, the expected number of stages of ADAPT in Table 1 ranges from
1.5 to 2.07 and is less than 2 for all cases in Table 3. Therefore ADAPT is not much less
convenient to run than the FSS test (with only 1 stage), in contrast with group sequential
tests with 3, 4, 5 or more interim analyses of the accumulated data. In practical terms, this
can provide substantial savings in the operational costs of the trial by eliminating the need
for data monitoring at interim analyses since the updated sample size and stopping rule rule
are completely determined at the end of the pilot stage.
On the other hand, there are situations where adding an additional stage or increasing
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the maximum sample size may be desired, as pointed out by Cui, Huang, and Wang (1999)
and Lehmacher and Wassmer (1999). For example, (1999) cites a study protocol, which
was reviewed by the Food and Drug Administration, involving a Phase III group sequential
trial for evaluating the efficacy of a new drug to prevent myocardial infarction in patients
undergoing coronary artery bypass graft surgery. During interim analysis, the observed
incidence for the drug achieved a reduction that was only half of the target reduction assumed
in the calculation of the maximum sample size M , resulting in a proposal to increase the
maximum sample size to Nmax. The basic idea underlying the proposed test in Section 2 can
be easily modified to allow increase of the maximum sample size from M to no more than
Nmax after the second stage, resulting in a test with at most four stages. The type I error
probability of the modified test can be computed numerically by recursive integration or by
Monte Carlo simulations, as described in Section 2.
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